Avalo Therapeutics sets up $200 million at-the-market stock sale with JefferiesNov 5PartnershipAvalo Therapeutics, Inc.
Avalo Therapeutics files $200 million at-the-market stock offering with JefferiesNov 5FinancingAvalo Therapeutics, Inc.
Avalo reports Q3 2026 results, plans Phase 3 start for abdakibart in HS in H1 2027Nov 5Quarterly updateAvalo Therapeutics, Inc.
Avalo reports Q2 2026 results, plans Phase 3 start for abdakibart in HS in H1 2027Aug 6Quarterly updateAvalo Therapeutics, Inc.